Based on our results with our proprietary CD30 targeting ADC, we published an article in Bioconjugate Chemistry. We compared our technology McSAF Inside to maleimide used in Adcetris.
We showed an increased stability and relevant in vivo efficacy in a lymphoma mouse model while treatment was well tolerated in rats.